Search
Proposed Priority Review for Alice's "Furmonertinib" in New Indication for Advanced Lung Cancer
3 week ago /
Read about 0 minute
Author：小编
Alice Pharmaceutical's Furmonertinib Tablets have been recommended for priority review for the treatment of adult patients diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring specific EGFR mutations. This conditional approval hinges on the outcomes of a single-arm clinical trial, with full approval contingent upon the results of a subsequent confirmatory clinical trial. As a third-generation EGFR-TKI, Furmonertinib has already secured approvals for both second-line and first-line treatment indications and is listed in the national medical insurance catalog, thereby offering patients a broadened spectrum of treatment options along with financial relief.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
